• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Inpatient Use of Benzodiazepines for Patients With Substance Use Disorders
Clinical Update

Inpatient Use of Benzodiazepines for Patients With Substance Use Disorders

January 31, 2024
Audrey Abelleira, PharmD, BCPP
From The Carlat Hospital Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Audrey Abelleira, PharmD, BCPP. Clinical pharmacist practitioner, VA Connecticut Healthcare System; clinical instructor, Yale School of Medicine, New Haven, CT.

Dr. Abelleira has no financial relationships with companies related to this material.

If you work in a psychiatric unit, you probably often face the challenge of managing patients with co-occurring substance use disorders (SUDs). Benzodiazepines offer considerable benefits in the management of alcohol withdrawal symptoms and agitation, but they require a mindful approach when you’re working with patients with a history of alcohol use disorder (AUD) or other SUDs. Approximately 12.6% of the US population reported benzodiazepine use within the previous year, with misuse accounting for nearly 20% of all use (Maust DT et al, Psychiatr Serv 2019;70(2):97–106). Risk of misuse is highest for adults 18–25, and concomitant cannabis or alcohol use has been associated with a higher risk of misuse. Given the potential risks of cognitive impairment, falls, dependence, misuse, and even higher mortality rate among patients with AUD, the use of benzodiazepines warrants caution (Heikkinen M et al, Addiction 2021;116(8):1990–1998). This article provides an overview of important considerations when using benzodiazepines for patients with SUDs in psychiatric inpatient settings.

Inpatient use of benzodiazepines

Benzodiazepines rank among the most frequently misused substances, and misuse is prevalent among patients with AUD. Both benzodiazepines and alcohol act via the ­GABAergic system, leading to a potent combined effect that increases the likelihood of adverse outcomes, including, in severe cases, fatal overdoses. Further, exposure to benzodiazepines can trigger a return to use for patients in recovery from AUD. So, before prescribing benzodiazepines, thoroughly check the patient’s history, their substance use patterns, and any factors that might increase risk of a relapse, such as poor physical health, poor sleep, or psychosocial stressors (Sliedrecht W et al, Psychiatry Res 2019;278:97–115).

A good rule of thumb is to keep the duration of benzodiazepine use as short and the dosage as low as possible, considering that tolerance and physical dependence on benzodiazepines can develop in just one week (Vinkers CH et al, Adv Pharmacol Sci 2012;2012:416864). In the days leading up to discharge, taper the dosage gradually since abrupt discontinuation can produce a rebound of anxiety, insomnia, and irritability. Typically, a dose reduction of 25%–50% every week is well tolerated, but you can taper the dose as quickly as every two or three days in many cases. A taper is not necessary if the benzodiazepine use was sporadic during the inpatient admission. 

For the medical management of alcohol withdrawal, I prefer long-acting benzodiazepines, such as chlordiazepoxide (Librium) or diazepam (Valium), over short-acting agents like alprazolam (Xanax). This is because a longer half-life allows for more consistent management of withdrawal symptoms and a smoother, more tolerable experience for the patient. The pharmacokinetic profiles of chlordiazepoxide and diazepam are similar; however, both have been subject to recent drug shortages, so the choice between them will largely be guided by hospital formulary and availability. Typical symptom-triggered doses of chlordiazepoxide are 25–100 mg PO, and the range for diazepam is 5–10 mg PO, as needed every four to six hours based on severity of withdrawal symptoms. Lorazepam (Ativan), while not a long-acting benzodiazepine, is a good option for elderly patients or those with liver disease as it lacks active metabolites, with doses of 2–4 mg every four to six hours. I recommend symptom-triggered dosing as a way to minimize overall benzodiazepine exposure (for more on symptom-triggered dosing, see Q&A with Dr. Ponce Martinez in this issue).

For all patients, I make sure to optimize non-benzodiazepine treatment options that they can continue to utilize once discharged. Antidepressants, such as escitalopram or venlafaxine, are first-line pharmacotherapy for anxiety disorders and are my first considerations in formulating a benzodiazepine-sparing regimen (Szuhany KL and Simon NM, JAMA 2022;328(24):2431–2445). Antipsychotics, specifically second-generation agents like olanzapine, are an effective alternative to benzodiazepines for managing agitation. These often act faster and produce a lower risk of oversedation than benzodiazepines (Amore M et al, Front Psychiatry 2021;12:628965). I also often prescribe gabapentinoids (gabapentin and pregabalin) for anxiety. When used short term, pregabalin appears as effective as lorazepam and has the added advantage of improving anxiety symptoms in cases refractory to antidepressants. The risk of withdrawal or rebound anxiety symptoms is minimal when discontinuing pregabalin following long-term use. Like pregabalin, gabapentin improves anxiety symptoms and enhances the therapeutic response to antidepressants. Gabapentin doses are 300–3600 mg per day, and pregabalin doses are 150–600 mg per day (Greenblatt H and Greenblatt DJ, Clin Pharmacol Drug Dev 2018;7(3):228–232).

CARLAT VERDICT 

Understanding a patient’s substance use history and their susceptibility to SUDs is crucial in making informed decisions about benzodiazepine use. If you need to prescribe benzodiazepines for withdrawal symptoms or acute anxiety/ agitation, keep the duration short and taper the medications prior to discharge. Don’t overlook alternative medications for treating anxiety, like second-generation antipsychotics, antidepressants, gabapentin, and pregabalin.


Hospital Psychiatry Clinical Update
KEYWORDS agitation antidepressants antipsychotics anxiety benzodiazepines gabapentin pregabalin substance use disorders
    Audrey Abelleira, PharmD, BCPP

    Deprescribing Benzos: A How-To Guide

    More from this author
    www.thecarlatreport.com
    Issue Date: January 31, 2024
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Substance Use Disorders, CHPR, January/February/March 2024
    Wernicke’s Encephalopathy and Korsakoff’s Syndrome
    Substance-Induced Psychosis: Diagnostic Dilemmas and Treatment Options
    Alcohol Withdrawal: What to Watch For on the Psychiatric Inpatient Unit
    Inpatient Use of Benzodiazepines for Patients With Substance Use Disorders
    Sublingual Dexmedetomidine for Acute Agitation in Bipolar Disorder
    Are Individuals With Major Depressive Symptoms More Likely to Own a Gun in the United States?
    Initiation of Gender-Affirming Hormones and Mental Health Outcomes
    CME Post-Test, Substance Use Disorders, CHPR, January/February/March 2024
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.